Regenxbio Inc (RGNX) - Total Assets
Based on the latest financial reports, Regenxbio Inc (RGNX) holds total assets worth $341.89 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Regenxbio Inc (RGNX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Regenxbio Inc - Total Assets Trend (2013–2025)
This chart illustrates how Regenxbio Inc's total assets have evolved over time, based on quarterly financial data. See net assets of Regenxbio Inc for net asset value and shareholders' equity analysis.
Regenxbio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Regenxbio Inc's total assets of $341.89 Million consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.6% |
| Accounts Receivable | $27.38 Million | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Regenxbio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RGNX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regenxbio Inc's current assets represent 62.1% of total assets in 2025, a decrease from 87.9% in 2013.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2025, down from 44.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Regenxbio Inc Competitors by Total Assets
Key competitors of Regenxbio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Regenxbio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 2.93 | 4.78 |
| Quick Ratio | 2.62 | 2.93 | 4.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $115.41 Million | $206.51 Million | $345.83 Million |
Regenxbio Inc - Advanced Valuation Insights
This section examines the relationship between Regenxbio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 37.35 |
| Latest Market Cap to Assets Ratio | 1.11 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | $453.03 Million |
| Market Capitalization | $500.95 Million USD |
Valuation Analysis
Above Book Valuation: The market values Regenxbio Inc's assets above their book value (1.11x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Regenxbio Inc's assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Regenxbio Inc (2013–2025)
The table below shows the annual total assets of Regenxbio Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $453.03 Million | -2.78% |
| 2024-12-31 | $465.99 Million | -18.81% |
| 2023-12-31 | $573.97 Million | -31.12% |
| 2022-12-31 | $833.27 Million | -25.19% |
| 2021-12-31 | $1.11 Billion | +57.29% |
| 2020-12-31 | $708.16 Million | +42.23% |
| 2019-12-31 | $497.91 Million | -8.44% |
| 2018-12-31 | $543.81 Million | +173.72% |
| 2017-12-31 | $198.68 Million | +15.02% |
| 2016-12-31 | $172.73 Million | -21.97% |
| 2015-12-31 | $221.38 Million | +6241.45% |
| 2014-12-31 | $3.49 Million | +39.08% |
| 2013-12-31 | $2.51 Million | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more